Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 20/20 | 0.82 |
| ▸ | KIT | P10721 | 1/20 | 0.82 |
| ▸ | MTOR | P42345 | 1/20 | 0.82 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.82 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.82 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.82 |
| ▸ | STK38 | Q15208 | 1/20 | 0.82 |
| ▸ | BRSK2 | Q8IWQ3 | 1/20 | 0.82 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.82 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.82 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15036974 | 1.00 | TTK (0.82) | TTKKITMTORMAPK8MAPK9 | |
| SCHEMBL15020285 | 0.93 | TTK (0.70) | TTKKITMTORMAPK8MAPK9 | |
| SCHEMBL15415858 | 0.92 | TTK (0.85) | TTKKITMTORMAPK8MAPK9 | |
| SCHEMBL15434339 | 0.92 | TTK (0.85) | TTKKITMTORMAPK8MAPK9 | |
| SCHEMBL15020325 | 0.92 | TTK (0.75) | TTKKITMTORMAPK8MAPK9 | |
| SCHEMBL15036977 | 0.92 | TTK (0.75) | TTKKITMTORMAPK8MAPK9 | |
| SCHEMBL16295272 | 0.91 | TTK (0.68) | TTKKITMTORMAPK8MAPK9 | |
| SCHEMBL16736973 | 0.91 | TTK (0.67) | TTKKITMTORMAPK8MAPK9 | |
| Bay-1161909 SCHEMBL19729431 | 0.90 | TTK (1.00) | TTKKITMTORMAPK8MAPK9 | |
| Bay-1161909 SCHEMBL15036597 | 0.90 | TTK (1.00) | TTKKITMTORMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663510-B2 | Substituted triazolopyridines and their use as TTK inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| US-9663510-B2 | Substituted triazolopyridines and their use as TTK inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| US-9388177-B2 | Method for preparing substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-12 | — | — | US | disclosed |
| US-9388177-B2 | Method for preparing substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20150210683-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-30 | — | — | US | disclosed |
| US-20150210683-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-30 | — | — | US | disclosed |
| EP-2791136-B1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | BAYER IP GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| EP-2791136-B1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | BAYER IP GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-20150148542-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| US-20150148542-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| EP-2872506-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-05-20 | — | — | EP | disclosed |
| EP-2791136-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-10-22 | — | — | EP | disclosed |
| WO-2014009219-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009219-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013087579-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013087579-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210683-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | TTK, TXK, ITK | TTK 1/4885KIT 393/4885MTOR 1921/4885 |
| US-20150148542-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | QDPR, CYP3A5, CYP3A7 | TTK 1843/4885KIT 56/4885MTOR 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.